The Promise of Liquid Biopsy in Colorectal Cancer

Clinical Advances in Hematology and Oncology

Volumn 12, Issue 10, 2014, Pages 688-689

  Diaz, Luis Alberto ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER PATIENT; CLINICAL TRIAL (TOPIC); COLONOSCOPY; COLORECTAL CANCER; DISEASE COURSE; DNA SEQUENCE; HUMAN; LIQUID BIOPSY; RECURRENT DISEASE; TUMOR BIOPSY; BLOOD; COLON; COLORECTAL TUMOR; GENETICS; INTERVIEW; PATHOLOGY; RECTUM;

DNA; TUMOR MARKER;

BIOMARKERS, TUMOR; COLON; COLORECTAL NEOPLASMS; DNA, NEOPLASM; HUMANS; RECTUM;

EID: 84908126636     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013;368(13):1199-1209.
2. Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014;32(6):579-586.
3. Diaz LA Jr, Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486(7404):537-540.
4. Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985-990.
5. Forshew T, Murtaza M, Parkinson C, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med. 2012;4(136):136ra168.
6. Mouliere F, El Messaoudi S, Pang D, Dritschilo A, Thierry AR. Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer. Mol Oncol. 2014;8(5):927-941.
7. Murtaza M, Dawson SJ, Tsui DW, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 2013;497(7447):108-112.
8. Thierry AR, Mouliere F, El Messaoudi S, et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med. 2014;20(4):430-435.